Skip to main content
SpringerLink
Log in

Potential biomarker of circulating hsa-miR-1273g-3p level for detection of recurrent epithelial ovarian cancer

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

Ovarian cancer (OC) is first gynaecologic cancer that causes women death and epithelial ovarian cancer (EOC) is the most lethal ovarian cancer type. While treatment is commonly successful, some cases (10–20%) show resistance to chemotherapy which is followed by recurrence. MicroRNA (miRNA) based diagnosis methods are slightly important for recurrent ovarian cancer diagnosis. We aimed to detect novel circulating miRNAs to be used as an early diagnosis and prediction tools for recurrent EOC.

Methods

In this study, recurrent EOC serum samples and healthy control serum samples were compared for miRNA expression analysis by microarray. Microarray results were analyzed by bioinformatics tools and differentially expressed hsa-miR-1273g-3p was obtained. After microarray analysis, differentially expressed hsa-miR-1273g-3p was validated by Real-Time PCR (RT-qPCR). The relation between target genes of hsa-miR-1273g-3p and ovarian cancer were examined by Pathway Studio® (v.11.4.0.8).

Results

The expression of hsa-miR-1273g-3p was found to be significantly down-regulated by t test Bonferroni FWER corrected p < 0.05 and fold change > 2, in recurrence EOC compare with healthy controls groups. The RT-qPCR results confirmed that relative expressions of the serum hsa-miR-1273g-3p were significantly down-regulated in patients with recurrent EOC (p = 0.0275). Serum hsa-miR-1273g-3p levels could discriminate patients with recurrent EOC from healthy controls, with a power area under the curve (AUC) of 0.7.

Conclusion

This study suggested that hsa-miR-1273g-3p plays a significant role in regulation of related genes, which are TNF-alfa, COL1A1, MMP-2, MMP-9, with recurrent EOC outcome. hsa-miR-1273g-3p may be used as a prognostic marker for recurrent EOC after chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Nakamura K, Sawada K, Yoshimura A, Kinose Y, Nakatsuka E, Kimura T (2016) Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol Cancer 15(1):48. https://doi.org/10.1186/s12943-016-0536-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Chong GO, Jeon HS, Han HS, Son JW, Lee YH, Hong DG, Lee YS, Cho YL (2015) Differential microRNA expression profiles in primary and recurrent epithelial ovarian cancer. Anticancer Res 35(5):2611–2617

    CAS  PubMed  Google Scholar 

  3. Laios A, O’Toole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, D’Arcy T, McGuinness E, Sheils O, Sheppard B, Ol J (2008) Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 7:35. https://doi.org/10.1186/1476-4598-7-35

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Retamales-Ortega R, Oróstica L, Vera C, Cuevas P, Hernández A, Hurtado I, Vega M, Romero C (2017) Role of nerve growth factor (NGF) and miRNAs in epithelial ovarian cancer. Int J Mol Sci 18:507. https://doi.org/10.3390/ijms18030507

    Article  CAS  PubMed Central  Google Scholar 

  5. Molasy M, Walczak A, Szaflik J, Szaflik JP, Majsterek I (2017) MicroRNAs in glaucoma and neurodegenerative diseases. J Hum Genet 62(1):105–112. https://doi.org/10.1038/jhg.2016.91

    Article  CAS  PubMed  Google Scholar 

  6. Barwari T, Joshi A, Mayr M (2016) MicroRNAs in cardiovascular disease. J Am Coll Cardiol 68(23):2577–2584. https://doi.org/10.1016/j.jacc.2016.09.945

    Article  CAS  PubMed  Google Scholar 

  7. Vienberg S, Geiger J, Madsen S, Dalgaard LT (2017) MicroRNAs in metabolism. Acta Physiol (Oxf) 219(2):346–361. https://doi.org/10.1111/apha.12681

    Article  CAS  Google Scholar 

  8. Reddy KB (2015) MicroRNA (miRNA) in cancer. Cancer Cell Int 15:38. https://doi.org/10.1186/s12935-015-0185-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Ruan K, Fang X, Ouyang G (2009) MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 285(2):116–126. https://doi.org/10.1016/j.canlet.2009.04.031

    Article  CAS  PubMed  Google Scholar 

  10. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK (2009) MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 8(5):1055–1066. https://doi.org/10.1158/1535-7163.MCT-08-1046

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. James A, Daley CM, Greiner KA (2011) “Cutting” on cancer: attitudes about cancer spread and surgery among primary care patients in the USA. Soc Sci Med 73(11):1669–1673. https://doi.org/10.1016/j.socscimed.2011.09.017

    Article  PubMed  PubMed Central  Google Scholar 

  12. Gumusoglu E, Gunel T (2018) The role of circulating biomarkers in the early diagnosis of ovarian cancer. Ovarian Cancer (in press)

  13. Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, Liu J (2009) ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol 22(6):817–823. https://doi.org/10.1038/modpathol.2009.35

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Yang H, Kong W, He L, Zhao JJ, O’Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ (2008) MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68(2):425–433. https://doi.org/10.1158/0008-5472.CAN-07-2488

    Article  CAS  PubMed  Google Scholar 

  15. Ivashchenko A, Berillo O, Pyrkova A, Niyazova R (2014) Binding sites of miR-1273 family on the mRNA of target genes. Biomed Res Int 2014:620530. https://doi.org/10.1155/2014/620530

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Cha SY, Choi YH, Hwang S, Jeong JY, An HJ (2017) Clinical impact of microRNAs associated with cancer stem cells as a prognostic factor in ovarian carcinoma. J Cancer 8(17):3538–3547. https://doi.org/10.7150/jca.20348

    Article  PubMed  PubMed Central  Google Scholar 

  17. Ye Z, Li ZH, He SZ (2017) miRNA-1273g-3p involvement in development of diabetic retinopathy by modulating the autophagy-lysosome pathway. Med Sci Monit 23:5744–5751

    Article  Google Scholar 

  18. Balkwill F (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13(2):135–141

    Article  CAS  Google Scholar 

  19. Kwong J, Chan FL, Wong KK, Birrer MJ, Archibald KM, Balkwill FR, Berkowitz RS, Mok SC (2009) Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. Neoplasia 11(6):529–541

    Article  CAS  Google Scholar 

  20. Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR (1993) Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 91(5):2194–2206. https://doi.org/10.1172/JCI116446

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Mori K, Hatamochi A, Ueki H, Olsen A, Jimenez SA (1996) The transcription of human alpha 1(I) procollagen gene (COL1A1) is suppressed by tumour necrosis factor-alpha through proximal short promoter elements: evidence for suppression mechanisms mediated by two nuclear-factor binding sites. Biochem J 319(Pt 3):811–816

    Article  CAS  Google Scholar 

  22. Li AQ, Si JM, Shang Y, Gan LH, Guo L, Zhou TH (2010) Construction of COL1A1 short hairpin RNA vector and its effect on cell proliferation and migration of gastric cancer cells. Zhejiang Da Xue Xue Bao Yi Xue Ban 39(3):257–263

    CAS  PubMed  Google Scholar 

  23. Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, Rizzo S, van der Zee A, Plumb JA, Brown R (2012) Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 31(42):4567–4576. https://doi.org/10.1038/onc.2011.611

    Article  CAS  PubMed  Google Scholar 

  24. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R (2004) The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 10(13):4420–4426. https://doi.org/10.1158/1078-0432.CCR-03-0732

    Article  CAS  PubMed  Google Scholar 

  25. Roy R, Yang J, Moses MA (2009) Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27(31):5287–5297. https://doi.org/10.1200/JCO.2009.23.5556

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Zhang Y, Chen Q (2017) Relationship between matrix metalloproteinases and the occurrence and development of ovarian cancer. Braz J Med Biol Res 50(6):e6104. https://doi.org/10.1590/1414-431X20176104

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Tholen S, Biniossek ML, Gansz M, Ahrens TD, Schlimpert M, Kizhakkedathu JN, Reinheckel T, Schilling O (2014) Double deficiency of cathepsins B and L results in massive secretome alterations and suggests a degradative cathepsin-MMP axis. Cell Mol Life Sci 71(5):899–916. https://doi.org/10.1007/s00018-013-1406-1

    Article  CAS  PubMed  Google Scholar 

  28. Hijova E (2005) Matrix metalloproteinases: their biological functions and clinical implications. Bratisl Lek Listy 106(3):127–132

    CAS  PubMed  Google Scholar 

  29. Poon SL, Klausen C, Hammond GL, Leung PC (2011) 37-kDa laminin receptor precursor mediates GnRH-II-induced MMP-2 expression and invasiveness in ovarian cancer cells. Mol Endocrinol 25(2):327–338. https://doi.org/10.1210/me.2010-0334

    Article  CAS  PubMed  Google Scholar 

  30. Laios A, Mohamed BM, Kelly L, Flavin R, Finn S, McEvoy L, Gallagher M, Martin C, Sheils O, Ring M, Davies A, Lawson M, Gleeson N, D’Arcy T, d’Adhemar C, Norris L, Langhe R, Saadeh FA, O’Leary JJ, O’Toole SA (2013) Pre-Treatment of platinum resistant ovarian cancer cells with an MMP-9/MMP-2 inhibitor prior to cisplatin enhances cytotoxicity as determined by high content screening. Int J Mol Sci 14(1):2085–2103. https://doi.org/10.3390/ijms14012085

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported by Research Foundation of the University of Istanbul (Project no: 51472/2014).

Author information

Authors and Affiliations

  1. Department of Molecular Biology and Genetics, Faculty of Science, Istanbul University, 34134 Sehzadebasi Ave, 34134, Istanbul, Turkey

    Tuba Günel, Ece Gumusoglu, Berkcan Dogan, Fatma Betül Ertem & Mohammad Kazem Hosseini

  2. Computer Engineering Department, Engineering, Architecture Faculty, Istanbul Arel University, 34537, Istanbul, Turkey

    Nazife Cevik

  3. Department of Obstetrics and Gynecology, Sanliurfa Training and Research Hospital, 63300, Sanliurfa, Turkey

    Taylan Senol

  4. Department of Obstetrics and Gynecology, Istanbul Medical Faculty, Istanbul University, 34104, Istanbul, Turkey

    Samet Topuz

  5. Medicus Health Centre, 34365, Istanbul, Turkey

    Kilic Aydinli

Authors
  1. Tuba Günel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ece Gumusoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Berkcan Dogan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fatma Betül Ertem
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohammad Kazem Hosseini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nazife Cevik
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Taylan Senol
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Samet Topuz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kilic Aydinli
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TG: conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, project administration supervision validation writing—original draft writing—review and editing. EG: formal analysis, methodology, software, validation, visualization, writing—original draft, writing—review and editing. BD: data curation, methodology, validation, visualization, writing—original draft, writing—review and editing. FBE: formal analysis, methodology, validation, writing—original draft, writing—review and editing. MKH: data curation, methodology, validation, formal analysis. NC: data curation, formal analysis, software. TS: data curation, resources. ST: data curation, project administration, resources, supervision. KA: data curation, resources.

Corresponding author

Correspondence to Tuba Günel.

Ethics declarations

Conflict of interest

The authors declare that there are no conflicts of interest.

Ethical approval

All patients and volunteers have been asked to sign and confirm the informed consent, whole sample collection and analysis processes are ethically approved by Istanbul University Faculty of Medicine Clinical Researches Ethics Committee (Permission no: 2014/1175) on 08/08/2014.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Günel, T., Gumusoglu, E., Dogan, B. et al. Potential biomarker of circulating hsa-miR-1273g-3p level for detection of recurrent epithelial ovarian cancer. Arch Gynecol Obstet 298, 1173–1180 (2018). https://doi.org/10.1007/s00404-018-4913-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-018-4913-3

Keywords

Search

Navigation